P. Rosa-Neto

Tau‐PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head‐to‐head comparison of Flortaucipir and MK6240

Abstract INTRODUCTION We compared the association between mild behavioral impairment (MBI) and first‐ versus second‐generation tau‐positron emission tomography (PET) tracers in preclinical and prodromal Alzheimer's disease (AD). METHODS We assessed 110 individuals with head‐to‐head [18F]MK6240 and [18F]Flortaucipir tau...

A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease

Key Points Question Can a harmonized visual reading framework enable reliable, tracer-agnostic staging of tau positron emission tomography (PET) pathology for clinical use? Findings In this multicenter cross-sectional study of 681 participants scanned with multiple tau PET radiotracers, a 5-class harmonized visual read...

Metabolic brain network reorganization precedes clinical conversion in Alzheimer’s disease

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

Plasma Biomarkers for Neocortical Tau Burden.

This multicohort study demonstrated how including additional plasma proteins significantly enhanced the performance of p-tau217 in predicting advanced tau pathology among amyloid-positive individuals, suggesting a multiprotein approach may offer a viable and scalable alternative to tau PET staging in clinical or resear...

Predicting continuous amyloid PET levels with CSF and plasma brain‐derived p‐tau217

Conventional phosphorylated tau (p‐tau)217 reliably identifies amyloid positron emission tomography (PET) positivity, but its ability to capture the full Aβ continuum is limited.

Differential associations of tau extent and load with brain metabolic and cognitive dysfunction in Alzheimer's disease

Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.

Blood-based biomarkers of Alzheimer’s disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

In low- and middle-income countries, Alzheimer’s disease (AD) constitutes a growing public health burden. However, AD biomarkers research remains underrepresented in African populations. This study assesses core biomarkers of AD and their relevance in the African context as potential aid in clinical diagnosis. Nigerian...

Validation and normative data for the Multilingual Naming Test (MINT) in French-speaking Quebec adults over 40.

The results show that the MINT is adequately valid and effective to replace the BNT in neuropsychological assessment in the Quebec French population and performed better at discriminating dementia from cognitively unimpaired participants than at identifying MCI.

Association Between Plasma Phosphorylated Tau-217 and Cognition in Parkinson's Disease.

The results suggest that co-morbid AD pathology is not a major contributor to early cognitive changes in this sample of PD patients without dementia.

Association Between Plasma GFAP and Medial Temporal Atrophy and Cognition in Amyloid-Negative Cerebrovascular Disease.

In Aβ-negative cognitively impaired individuals with high cerebrovascular burden, elevated plasma GFAP is associated with medial temporal atrophy and cognitive decline, suggesting GFAP may capture astrocyte-reactivity relevant to vascular cognitive impairment beyond amyloid pathology.